Posts by: Forest Ray

Forest Ray

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

January 13, 2021January 13, 2021

PrimeC Earns Orphan Drug Designation in Europe

News

The European Medicines Agency has granted orphan drug designation to PrimeC, an investigational combination therapy for amyotrophic lateral sclerosis (ALS). PrimeC, developed by NeuroSense Therapeutics, also has received orphan drug ... Read more

January 12, 2021January 12, 2021

First Patient Enrolled in Pridopidine Arm of the HEALEY ALS Platform Trial

News

A pivotal clinical trial evaluating pridopidine for the treatment of amyotrophic lateral sclerosis (ALS) has enrolled its first participant, Prilenia Therapeutics, the medicine’s maker, announced. The Phase 2/3 study, ... Read more

December 10, 2020December 10, 2020

Cytokinetics Presents COURAGE-ALS Phase 3 Trial Plan for Testing Reldesemtiv

News

Cytokinetics is preparing a global Phase 3 trial that will enroll more than 500 people with early amyotrophic lateral sclerosis (ALS) to test its investigational therapy reldesemtiv in slowing ... Read more

November 20, 2020November 20, 2020

FDA Grants Orphan Drug Designation to SLS-005 for Slowing ALS Progression

News

The U.S. Food and Drug Administration (FDA) has awarded orphan drug designation to Seelos Therapeutics‘ SLS-005 (trehalose), a medication designed to slow the progression of amyotrophic lateral sclerosis (ALS), the ... Read more

November 17, 2020November 17, 2020

Radicava’s Effectiveness for ALS Not Established, Real-life Use Suggests

News

A review of Radicava (edaravone), an approved amyotrophic lateral sclerosis (ALS) treatment, found the medication generally well tolerated in real-life use by patients in six countries, matching reports from clinical ... Read more

November 11, 2020November 11, 2020

Global Phase 3 Study of Oral Edaravone to Treat ALS Fully Enrolled

News

The Phase 3 clinical trial investigating an oral suspension formulation of edaravone (MT-1186) in treating amyotrophic lateral sclerosis (ALS) is now fully enrolled, the therapy’s developer, Mitsubishi Tanabe Pharma America, announced. ... Read more

November 4, 2020November 4, 2020

1st Patient Enrolled in Phase 2a Trial Testing AT-1501 in ALS

News

Novus Therapeutics has enrolled the first patient in its Phase 2a trial of AT-1501 in adults with amyotrophic lateral sclerosis (ALS), the company announced in a press release. The ... Read more

October 23, 2020October 23, 2020

Catalent to Produce BrainStorm’s NurOwn Cell Therapy for ALS

News

Catalent Biologics has agreed to manufacture NurOwn, the cell-based therapy by BrainStorm Cell Therapeutics being evaluated in a soon-to-conclude pivotal trial as a possible treatment of amyotrophic lateral sclerosis (ALS). With ... Read more

October 19, 2020November 19, 2020

Lack of Testosterone Metabolite in Spinal Fluid May Be Linked to ALS

News

A metabolite of testosterone, dihydrotestosterone (DHT), is found at significantly lower levels in the cerebrospinal fluid of people with amyotrophic lateral sclerosis (ALS), a small study found. This metabolite, ... Read more

October 13, 2020October 13, 2020

Phase 2 Study of Pegcetacoplan in Recently Diagnosed Patients Opens

News

A Phase 2 and potentially pivotal study investigating pegcetacoplan (APL-2) as a potential treatment for amyotrophic lateral sclerosis (ALS) is now enrolling patients, Apellis Pharmaceuticals, the therapy’s developer, announced in a ... Read more

Pin It on Pinterest